Category: Morphic
-
Morphic holding’s CFO and COO sells shares worth over $2.45 million By Investing.com
•
In a recent move, Mark Chigerin, the chief financial officer and chief operating officer of Morphek Holdings, Inc. (NASDAQ: ), sold a significant number of the company’s shares. According to the latest filing, Chigerin sold 43,936 shares of common stock at various prices, with the transactions totaling more than $2.45…
-
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 billion By Reuters
•
(Reuters) – Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug developer Morphek surged 76% to $56.15 premarket after Lilly’s offer…